FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979358552> ?p ?o ?g. }

• W2979358552 abstract "Abstract Abstract 1056 Objective: Evaluate prognostic significance of immunophenotypically and functionally defined candidate leukemia stem cell populations. Background: Numerous studies have demonstrated that the population of CD34+/CD38dim (low to negative) cells is highly enriched for human hematopoietic stem cells. Another marker of stem cell-like phenotype can be assessed functionally by measuring the ability of the blasts to actively export DNA binding dye, Hoechst 33342 by flow cytometry giving rise to the so called “side population”. SP has also been widely linked to stem cell potential in both hematopoietic and non-hemtatopoietic tissues. The relationship between SP and CD34+/CD38dim phenotype is not entirely clear. Analogously, most human acute myeloid leukemias contain both a CD34+/ CD38dim population and a side population. CD34+/CD38dim population has been established as a source of AML cells with high self renewal potential. Less data exists for the role of SP in self renewal in AML. The relationship between the CD34+/CD38dim population and the side populations in AML has not been fully clarified. Methods: Twenty-two newly diagnosed AML patients were identified with CD34+ immunophenotype on the majority of leukemic blasts amongst patients enrolled on an IRB-approved protocol for analysis of blood and bone marrow samples. These patients then underwent induction chemotherapy, and response and duration of first complete remission (CR1) were determined. Wilcoxon rank sum test was used to compare stem cell populations with achievement of CR and FLT3 status; Kruskal-Wallis test to compare stem cell populations across cytogenetic categories and CR1 duration categories (more then 12 months, relapsed less than 12 months, no response), and Spearman correlation to assess correlation between age and stem cell population. For the purposes of analysis of AML prognosis fractions of blasts with CD38 expression below that of mature myeloid cells (CD38low) and those with no CD38 expression (CD38neg) expression were analyzed separately. Results: The median age of AML patients was 61 (range 19–84). 23% of the patients had favorable, 41% intermediate, and 36% poor risk cytogenetics 45% achieved complete remission. Median SP % was 0.04 (0-13.2), median CD38low % was 1.298 (0.02-17.4), and median CD38neg % was 0.01077 (0-0.92). We first analyzed the relationship between CD34+/CD38dim and SP phenotypes in normal and AML patients. 20 normal human bone marrow and 22 bone marrows from patients were investigated by flow cytometry. We demonstrate that normal human bone marrow SP is highly enriched for the most phenotypically immature CD34+/CD38dim small blasts likely representing the earliest identifiable hematopoietic precursors. Moreover, the highest dye efflux activity correlated with the least CD38. In contrast to normal marrow in AML, the SP did not correspond with CD38 expression levels. Most samples showed an SP phenotype that extended to include many CD38bright events more typical of lineage-committed progenitors. ABCG2 pump inhibitor Fumitremorgin C blocked dye efflux in all normal and all but one AML samples we tested. Side population did harbor the same cytogentic anbormalities as the bulk of blasts in 4/4 samples tested. SP percent did not correlate with age, cytogenetic risk category, response, CR1 duration, or Flt3 (all p>0.05). Percent of CD38low and CD38neg each negatively correlated with achievement of complete response to treatment (both p<0.01). Percent CD38neg correlated with length of CR1 (p=0.02). There was also a positive correlation with increasing age (both p=0.01) for both CD38low and CD38neg populations. Only percent CD38neg correlated with cytogenetic risk category (p=0.03). Conclusions: Expansion of less mature (CD38 lower) compartment of blasts may explain the adverse prognosis of patients with advanced age and poor cytogenetic predictors. Disclosures: Becker: Genzyme: Research Funding." @default.
• W2979358552 created "2019-10-18" @default.
• W2979358552 creator A5013754928 @default.
• W2979358552 creator A5028772063 @default.
• W2979358552 creator A5047580648 @default.
• W2979358552 creator A5051018931 @default.
• W2979358552 creator A5056405520 @default.
• W2979358552 creator A5057920623 @default.
• W2979358552 creator A5063440051 @default.
• W2979358552 creator A5079953387 @default.
• W2979358552 date "2010-11-19" @default.
• W2979358552 modified "2023-10-11" @default.
• W2979358552 title "CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)." @default.
• W2979358552 doi "https://doi.org/10.1182/blood.v116.21.1056.1056" @default.
• W2979358552 hasPublicationYear "2010" @default.
• W2979358552 type Work @default.
• W2979358552 sameAs 2979358552 @default.
• W2979358552 citedByCount "0" @default.
• W2979358552 crossrefType "journal-article" @default.
• W2979358552 hasAuthorship W2979358552A5013754928 @default.
• W2979358552 hasAuthorship W2979358552A5028772063 @default.
• W2979358552 hasAuthorship W2979358552A5047580648 @default.
• W2979358552 hasAuthorship W2979358552A5051018931 @default.
• W2979358552 hasAuthorship W2979358552A5056405520 @default.
• W2979358552 hasAuthorship W2979358552A5057920623 @default.
• W2979358552 hasAuthorship W2979358552A5063440051 @default.
• W2979358552 hasAuthorship W2979358552A5079953387 @default.
• W2979358552 hasConcept C10205521 @default.
• W2979358552 hasConcept C109159458 @default.
• W2979358552 hasConcept C126322002 @default.
• W2979358552 hasConcept C143998085 @default.
• W2979358552 hasConcept C159912055 @default.
• W2979358552 hasConcept C196166836 @default.
• W2979358552 hasConcept C203014093 @default.
• W2979358552 hasConcept C2776611710 @default.
• W2979358552 hasConcept C2776694085 @default.
• W2979358552 hasConcept C2776863199 @default.
• W2979358552 hasConcept C2778461978 @default.
• W2979358552 hasConcept C2778729363 @default.
• W2979358552 hasConcept C2779282312 @default.
• W2979358552 hasConcept C2780007613 @default.
• W2979358552 hasConcept C2780546549 @default.
• W2979358552 hasConcept C28328180 @default.
• W2979358552 hasConcept C2908647359 @default.
• W2979358552 hasConcept C502942594 @default.
• W2979358552 hasConcept C54355233 @default.
• W2979358552 hasConcept C553184892 @default.
• W2979358552 hasConcept C55427017 @default.
• W2979358552 hasConcept C71924100 @default.
• W2979358552 hasConcept C86803240 @default.
• W2979358552 hasConcept C99454951 @default.
• W2979358552 hasConceptScore W2979358552C10205521 @default.
• W2979358552 hasConceptScore W2979358552C109159458 @default.
• W2979358552 hasConceptScore W2979358552C126322002 @default.
• W2979358552 hasConceptScore W2979358552C143998085 @default.
• W2979358552 hasConceptScore W2979358552C159912055 @default.
• W2979358552 hasConceptScore W2979358552C196166836 @default.
• W2979358552 hasConceptScore W2979358552C203014093 @default.
• W2979358552 hasConceptScore W2979358552C2776611710 @default.
• W2979358552 hasConceptScore W2979358552C2776694085 @default.
• W2979358552 hasConceptScore W2979358552C2776863199 @default.
• W2979358552 hasConceptScore W2979358552C2778461978 @default.
• W2979358552 hasConceptScore W2979358552C2778729363 @default.
• W2979358552 hasConceptScore W2979358552C2779282312 @default.
• W2979358552 hasConceptScore W2979358552C2780007613 @default.
• W2979358552 hasConceptScore W2979358552C2780546549 @default.
• W2979358552 hasConceptScore W2979358552C28328180 @default.
• W2979358552 hasConceptScore W2979358552C2908647359 @default.
• W2979358552 hasConceptScore W2979358552C502942594 @default.
• W2979358552 hasConceptScore W2979358552C54355233 @default.
• W2979358552 hasConceptScore W2979358552C553184892 @default.
• W2979358552 hasConceptScore W2979358552C55427017 @default.
• W2979358552 hasConceptScore W2979358552C71924100 @default.
• W2979358552 hasConceptScore W2979358552C86803240 @default.
• W2979358552 hasConceptScore W2979358552C99454951 @default.
• W2979358552 hasLocation W29793585521 @default.
• W2979358552 hasOpenAccess W2979358552 @default.
• W2979358552 hasPrimaryLocation W29793585521 @default.
• W2979358552 hasRelatedWork W2082117800 @default.
• W2979358552 hasRelatedWork W2137605834 @default.
• W2979358552 hasRelatedWork W2172817624 @default.
• W2979358552 hasRelatedWork W2229471147 @default.
• W2979358552 hasRelatedWork W2350703333 @default.
• W2979358552 hasRelatedWork W2355058510 @default.
• W2979358552 hasRelatedWork W2368459919 @default.
• W2979358552 hasRelatedWork W2384144479 @default.
• W2979358552 hasRelatedWork W2530799227 @default.
• W2979358552 hasRelatedWork W2547862644 @default.
• W2979358552 hasRelatedWork W2550400063 @default.
• W2979358552 hasRelatedWork W2573158594 @default.
• W2979358552 hasRelatedWork W2574366195 @default.
• W2979358552 hasRelatedWork W2587963343 @default.
• W2979358552 hasRelatedWork W2588927614 @default.
• W2979358552 hasRelatedWork W2613066044 @default.
• W2979358552 hasRelatedWork W2979706932 @default.
• W2979358552 hasRelatedWork W3000582628 @default.
• W2979358552 hasRelatedWork W3025100125 @default.
• W2979358552 hasRelatedWork W3032455582 @default.
• W2979358552 isParatext "false" @default.
• W2979358552 isRetracted "false" @default.

• next